Mechanisms of Interferon-alpha induced apoptosis in malignant cells

被引:0
|
作者
Lena Thyrell
Sven Erickson
Boris Zhivotovsky
Katja Pokrovskaja
Olle Sangfelt
Juan Castro
Stefan Einhorn
Dan Grandér
机构
[1] Cancer Center Karolinska (CCK),Department of Oncology and Pathology
[2] Karolinska Hospital and Institute,Department of Toxicology
[3] Institute of Environmental Medicine,undefined
[4] Karolinska Institute,undefined
来源
Oncogene | 2002年 / 21卷
关键词
interferon; apoptosis; caspase; mitochondria;
D O I
暂无
中图分类号
学科分类号
摘要
Interferon alpha (IFNα) has been used in the treatment of several types of cancer for almost 30 years, yet the mechanism(s) responsible for its anti-tumoral action remains unknown. A variety of cellular responses, including inhibition of cell growth and induction of apoptosis are induced by IFNs, and apoptotic induction by this cytokine has been proposed to be of importance for both its anti-tumoral in addition to its anti-viral responses. The aim of the present study was to delineate the pathways activated during IFNα-induced apoptosis in malignant cell lines. We found that apoptosis induced by IFNα was associated with activation of caspases-1, -2, -3, -8 and -9 and that this activation was a critical event. Caspase-3 activation was dependent on activity of caspases-8 and -9, moreover, activation of caspase-8 seems to be the upstream event in IFNα-induced caspase cascade. We also found loss of mitochondrial membrane potential as well as release of cytochrome c post IFN-treatment, clearly implicating the involvement of mitochondria in IFN-mediated apoptosis. Furthermore, IFNα-induced apoptosis was found to be independent on interactions between the Fas-receptor and its ligand. These studies form the basis for further investigations aiming to improve IFN therapy and the development of future strategies to overcome the IFN resistance observed in some malignancies.
引用
收藏
页码:1251 / 1262
页数:11
相关论文
共 50 条
  • [31] Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone
    J-J Kiladjian
    S Giraudier
    B Cassinat
    [J]. Leukemia, 2016, 30 : 776 - 781
  • [32] OUR EXPERIENCE WITH INTERFERON-ALPHA - METASTATIC MALIGNANT-MELANOMA
    MERIMSKY, O
    CHAITCHIK, S
    [J]. MOLECULAR BIOTHERAPY, 1992, 4 (03) : 135 - 138
  • [33] SUPPRESSION OF SACCHARIN-INDUCED MUTAGENICITY BY INTERFERON-ALPHA IN HUMAN RSA CELLS
    SUZUKI, N
    SUZUKI, H
    [J]. CANCER RESEARCH, 1995, 55 (19) : 4253 - 4256
  • [34] INDUCTION OF INTERFERON-ALPHA BY INTERFERON-BETA, BUT NOT OF INTERFERON-BETA BY INTERFERON-ALPHA, IN THE MOUSE
    ASANO, M
    HAYASHI, M
    YOSHIDA, E
    KAWADE, Y
    IWAKURA, Y
    [J]. VIROLOGY, 1990, 176 (01) : 30 - 38
  • [35] INTERFERON-ALPHA PREVENTS IN-VITRO APOPTOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA-B CELLS
    CHAOUCHI, N
    TERTIAN, G
    WALLON, C
    TAIEB, J
    AUFFREDOU, MT
    LEMOINE, F
    DELFRAISSY, JF
    VASQUEZ, A
    [J]. BLOOD, 1993, 82 (10) : A391 - A391
  • [36] INTERFERON-ALPHA IN LYMPHOMA
    ROHATINER, AZS
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1991, 79 : 26 - 29
  • [37] NEUROTOXICITY OF INTERFERON-ALPHA
    MERIMSKY, O
    CHAITCHIK, S
    [J]. ANTI-CANCER DRUGS, 1992, 3 (06) : 567 - 570
  • [38] MAJOR DEPRESSION SECONDARY TO INTERFERON-ALPHA: MECHANISMS, RESILIENCE, AND VULNERABILITY
    Lotrich, F. E.
    Rabinovitz, M.
    Pollock, B. G.
    [J]. JOURNAL OF INVESTIGATIVE MEDICINE, 2009, 57 (03) : 544 - 544
  • [39] IS INTERFERON-ALPHA ATHEROGENIC
    KUDER, P
    ABERGEL, A
    JOUANEL, P
    BONNY, C
    BRUN, H
    HENQUELL, C
    LAFEUILLE, H
    BOMMELAER, G
    [J]. HEPATOLOGY, 1995, 22 (04) : 1342 - 1342
  • [40] INTERFERON-ALPHA AND AUTOIMMUNITY
    PAPO, T
    PIETTE, JC
    DU, LTH
    GODEAU, P
    [J]. ANNALES DE MEDECINE INTERNE, 1993, 144 (05): : 357 - 366